prIME Masterclass in Colorectal Cancer - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

prIME Masterclass in Colorectal Cancer

A Multidisciplinary Interactive Workshop

Not a member of My prIME? Join now for instant access.

View downloadable slides for updates about the latest advances and emerging strategies in the management of colorectal cancer, and how to translate new evidence into clinical practice.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

May 24, 2018

Expiration Date

May 25, 2019

New era of CRC management

Keynote presentation I—New era of CRC management: Impact of tumor sidedness and molecular subtypes of CRC

Featured Expert: Scott Kopetz, MD, PhD, FACP

Pan-Asian ESMO-adapted guidelines for managing mCRC: Impact on clinical practice

Featured Expert: Takayuki Yoshino, MD, PhD

Optimizing outcomes in patients with CRC oligometastatic disease

Liver-only metastases: Importance of multidisciplinary treatment approach

Featured Expert: René Adam, MD, PhD

First-line therapy and continuum of care approach in mCRC

Selecting front-line therapy for mCRC

Featured Expert: Kun-Huei Yeh, MD, PhD

Continuum of care in mCRC

Featured Expert: Takayuki Yoshino, MD, PhD

Management of early stage CRC

Keynote presentation II—Immunotherapy in mCRC: MSI-high and beyond

Featured Expert: Kei Muro, MD

Future perspectives

CRC in the coming years: What can we expect?

Featured Expert: Scott Kopetz, MD, PhD, FACP

prIME Points™

Featured Expert: René Adam, MD, PhD

This educational activity is specifically designed for medical oncologists, gastroenterologists, surgical and radiation oncologists, and other healthcare professionals involved in the management of colorectal cancer (CRC).

After successful completion of this educational activity, participants should be able to:

  • Explain state-of-the-art management of early and metastatic CRC (mCRC), and evaluate current and emerging biomarkers to guide personalized therapy
  • Identify multidisciplinary treatment approaches that may lead to optimal treatment outcomes for patients with liver-only metastases
  • Select optimal front-line treatment for mCRC and assess sequencing strategies beyond disease progression
  • Evaluate treatment options for metastatic BRAF-mutant mCRC
  • Describe emerging agents in mCRC, including immunotherapy-based combinations

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Adam has disclosed that he has received fees for speaking and teaching from Amgen, Merck, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Dr Kopetz has disclosed that he has received consulting fees from Amgen, Array, Bayer, Genentech, and Taiho. He also has ownership interest in MolecularMatch. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Muro has disclosed that he has received honoraria for promotional speaker’s bureaus from Chugai Pharmaceuticals, Eli Lilly, Merck Serono, Taiho Pharmaceutical, Takeda Pharmaceutical, and Yakult Honsha. He has also disclosed independent contracting for Daiichi Sankyo, Gilead Sciences, Kyowa Hakko Kirin, MSD, Ono Pharmaceutical, and Shionogi Pharmaceutical. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Xu has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Yeh has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Yoshino has disclosed that he has received honorarium for promotional speaker’s bureaus from Taiho Pharmaceutical Co., Ltd; Chugai Pharmaceuticals Co., Ltd; and Eli Lilly Japan K.K. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.